Johnson & Johnson vs Pfizer JNJ vs PFE
Johnson & Johnson and Pfizer on one sheet: valuation multiples, growth, margins, debt, dividends and returns, each section labelled with the period it covers, from the companies' filings. Add or remove a stock above the sheet; the link holds the set.
What differs most
- Return on equity: Johnson & Johnson 19.7%, Pfizer 5.1%.
- Market value: Johnson & Johnson $641.07B, Pfizer $169.79B.
- Price / sales: Johnson & Johnson 6.5×, Pfizer 2.7×.
- Net margin: Johnson & Johnson 16.2%, Pfizer 6.8%.
Price return
2025-10-26 → 2026-10-26
JNJ+39.9%
PFE+20.3%
Profile
latestSector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Drug Manufacturers - General
Market value
$641.07B
$169.79B
Enterprise value
$668.81B
$232.01B
Employees
141,700
75,000
Revenue per employee (TTM)
$701K
$849K
Our models
nightlythe valuation on each stock's pagePrice vs model
5% overvalued vs model
39% undervalued vs model
Model range
$142–546
$24.96–113
Models in the headline
1
1
FCF growth priced in, at a 10% return
19.3%
13.3%
Every model, its assumptions and its range: JNJ valuation · PFE valuation. The growth priced in, at any return: JNJ reverse DCF · PFE reverse DCF.
Trading
close 2026-10-26Last close
$266.30
$29.79
52-week high
$278.43
$30.42
52-week low
$186.00
$23.67
Price vs 52-week high
−4.4%
−2.1%
Price vs 52-week low
+43.2%
+25.9%
Average daily volume / shares
0.3%
0.7%
Beta
0.23
0.28
Returns
to 2026-10-261 month
−1.8%
+3.9%
3 months
+1.1%
+21.4%
6 months
+17.1%
+10.3%
Year to date
+28.7%
+19.6%
1 year
+39.9%
+20.3%
1 year, dividends added
+42.6%
+27.3%
2 years
+65.5%
+4.7%
Valuation
JNJ price × TTM to Sep 2026 · PFE price × TTM to Jun 2026P/E (TTM)
40.5×
39.3×
P/E on consensus EPS (next FY)
24.0×
10.1×
Price / sales
6.5×
2.7×
EV / sales
6.7×
3.6×
EV / EBITDA
21.5×
17.2×
Price / book
7.9×
2.0×
Price / free cash flow (FY)
32.5×
18.7×
Free-cash-flow yield (FY)
3.1%
5.3%
Growth
TTM and FY2025Revenue growth (TTM)
—
—
Revenue growth, consensus next FY
+7.5%
−0.5%
Revenue, 3-year CAGR
5.6%
−14.6%
Revenue, 5-year CAGR
2.7%
8.5%
EPS growth (TTM)
—
—
EPS growth, consensus next FY
+0.7%
+117.3%
EPS, 3-year CAGR
17.9%
−37.1%
Free cash flow, 3-year CAGR
4.7%
−29.6%
Diluted shares, 3-year change
−8.8%
−0.8%
Profitability
JNJ TTM to Sep 2026 · PFE TTM to Jun 2026Gross margin (FY)†
67.9%
70.3%
Operating margin
25.5%
25.1%
EBITDA margin
31.2%
21.2%
Net margin
16.2%
6.8%
Free-cash-flow margin (FY)
20.9%
14.5%
Return on equity
19.7%
5.1%
Return on assets
8.2%
2.2%
Asset turnover
0.50
0.32
† Gross margin (FY): As filed. Companies draw the cost-of-revenue line in different places, so gross margins of two companies in one industry can differ for that reason alone; operating margin does not depend on where the line is drawn.
Balance sheet
JNJ MRQ Sep 2026 · PFE MRQ Jun 2026Cash
$16.91B
$976.0M
Total debt
$44.65B
$63.19B
Net debt
$27.74B
$62.22B
Debt / equity
0.5×
0.7×
Net debt / EBITDA (TTM)
0.9×
4.6×
Interest coverage (FY)
26.4×
5.8×
Current ratio (FY)
1.03
1.16
Dividends
trailing 12 monthsDividend yield
2.0%
5.8%
Dividends per share
$5.28
$1.72
Payout ratio (of TTM EPS)
80.3%
227.2%
Dividend per share, 5-year CAGR
5.0%
2.1%
Frequency
Quarterly
Quarterly
Ownership and activity
last 90 days · latest 13FTracked superinvestors holding (13F)
15
11
Insider open-market buys (Form 4)
$0
$3.0M
Insider sales (Form 4)
$62.0M
$83K
Analyst upgrades
0
0
Analyst downgrades
0
0
Statements
JNJ income TTM to Sep 2026 · cash flow FY2025 · PFE income TTM to Jun 2026 · cash flow FY2025Revenue
$99.33B
$63.70B
EBITDA
$31.04B
$13.49B
Operating income
$25.32B
$15.98B
Net income
$16.09B
$4.33B
EPS (diluted)
$6.58
$0.76
Operating cash flow
$24.53B
$11.71B
Capital expenditure
−$4.83B
−$2.63B
Free cash flow
$19.70B
$9.08B
Dividends paid
$12.38B
$9.77B
Keep comparing
Johnson & Johnson against
Pfizer against
Statements, prices, dividends and consensus estimates from Financial Modeling Prep; insider trades from Form 4 and holdings from 13F. Refreshed nightly. A comparison of filed numbers, not a recommendation to buy, sell or hold any security.